论文部分内容阅读
目的探讨前列地尔联合缬沙坦治疗早期糖尿病肾病的临床疗效。方法回顾性分析我院68例早期糖尿病肾病患者,随机分为观察组和对照组。在常规治疗的同时,对照组服用缬沙坦,观察组采用前列地尔联合缬沙坦进行治疗。治疗时间为2周,比较二组患者的尿素氮、血肌酐和24h尿微量白蛋白等指标。结果观察组患者血肌酐和24h尿微量白蛋白的结果明显优于对照组,统计结果差异有统计学意义(P<0.05)。结论前列地尔联合缬沙坦疗法是一种安全、有效的早期糖尿病肾病治疗方法,值得临床应用推广。
Objective To investigate the clinical efficacy of alprostadil in combination with valsartan in the treatment of early diabetic nephropathy. Methods A retrospective analysis of 68 patients with early diabetic nephropathy in our hospital were randomly divided into observation group and control group. At the same time of routine treatment, the control group took valsartan, the observation group was treated with alprostadil plus valsartan. Treatment time was 2 weeks, comparing the two groups of patients with urea nitrogen, serum creatinine and 24h urine microalbumin and other indicators. Results The results of serum creatinine and 24h urine microalbumin in the observation group were significantly better than those in the control group, with statistical significance (P <0.05). Conclusion Alprostadil combined with valsartan is a safe and effective treatment for early diabetic nephropathy, which is worthy of clinical application.